The UBS group retains the outperformance note in RBC despite the regulatory concerns of the TBTF
UBS Group AG (NYSE: UBS) ranks among the best fundamental actions to buy according to healing funds. RBC Capital has retained its outperformance note on UBS Group AG (NYSE: UBS), but reduced its price objective for the Swiss banking giant of CHF31.50 to CHF29 on June 19. The move appears to be a response to the current “Too Big to Fail” (TBTF) regulatory situation for the bank of the bank.
RBC Capital quotes the longer implementation period of the proposal as a reduction factor, indicating that UB could absorb regulatory changes without further reducing shareholders’ payments. Although the new price objective is always higher than the current course of UBS’s action, the company’s evaluation methodology has been modified to take into account what it calls a “more severe result” on delayed assets and software.
While recognizing that he “will take time to have total visibility” on the situation, RBC Capital thinks that there is a better result for UBS Group AG (NYSE: UBS) despite immediate regulatory challenges.
The World Financial Services Company UBS Group AG (NYSE: UBS) offers a range of services, including investment banking and wealth management, individuals, businesses and institutions.
Although we recognize the potential of UBS as an investment, we believe that certain AI actions offer greater rising potential and have less risks. If you are looking for an extremely undervalued AI stock that should also benefit considerably from the Trump era tariffs and the excessive trend, see our free report on the Best short -term AI stock.
Read more: 10 best magic formula actions for 2025 and 10 best retirement actions to buy according to hedge funds
Disclosure: None.
